| Price | 23.525 on 19-03-2026 at 06:00:00 |
|---|---|
| Change | 0.00 0% |
| Buy | 0.00 |
| Sell | 0.00 |
| Last Trade: | Buy 107.00 at 22.20 |
| Day's Volume: | 0 |
| Last Close: | 23.525 |
| Open: | 0.00 |
| ISIN: | SE0015244520 |
| Day's Range | 0.00 - 0.00 |
| 52wk Range: | 20.45 - 41.40 |
| Market Capitalisation: | - |
| VWAP: | 0.00 |
| Shares in Issue: | 65.80m |
Bioinvent Inter (0H22) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 107 | 22.20 | SI Trade |
11:32:04 - 16-Mar-26 |
| Buy* | 107 | 22.20 | SI Trade |
11:32:04 - 16-Mar-26 |
| Buy* | 2,100 | 22.175 | SI Trade |
10:47:40 - 16-Mar-26 |
| Sell* | 25,000 | 22.60 | SI Trade |
15:31:36 - 13-Mar-26 |
| Sell* | 292 | 23.75 | SI Trade |
14:18:18 - 12-Mar-26 |
| Buy* | 500 | 23.025 | SI Trade |
11:39:20 - 10-Mar-26 |
| Sell* | 500 | 24.35 | SI Trade |
12:08:13 - 26-Feb-26 |
| Sell* | 20,000 | 26.25 | SI Trade |
13:46:47 - 25-Feb-26 |
| Sell* | 84 | 26.525 | SI Trade |
10:36:57 - 23-Feb-26 |
| Sell* | 84 | 26.525 | SI Trade |
10:36:57 - 23-Feb-26 |
Bioinvent Inter (0H22) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 26th Feb 2026 7:00 am | MFN | BioInvent International AB: Year-end report January 1 - December 31, 2025 |
| 5th Jan 2026 6:30 am | MFN | BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer |
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
